In this study, we assessed the impact of CYP2C9*2, CYP2C9*3 and/or VKORC1 -1639G>A/1173C>T single nucleotide polymorphisms on oral anticoagulants in a cohort of 231 Lebanese subjects who were on long-term warfarin or acenocoumarol maintenance therapy with International Normalized Ratio (INR) monitored at the
Manuscript 1: Esmerian MO, Mitri Z, Habbal MZ, Geryess E, Zaatari G, Alam S, Skouri HN, Mahfouz RA, Taher A, Zgheib NK. Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people. J Clin Pharmacol. 2011 Oct;51(10):1418-28 (PMID: 21148049).
Manuscript 2: Isma'eel HA, Sakr GE, Habib RH, Almedawar MM, Zgheib NK, Elhajj IH. Improved accuracy of anticoagulant dose prediction using a pharmacogenetic and artificial neural network-based method. Eur J Clin Pharmacol. 2014 Mar;70(3):265-73 (PMID: 24297344).
Lebanese subjects taking either warfarin
(Coumadin®) or acenocoumarol (Sintrom®) who had INR values determined at the
Referral for INR testing at the AUBMC lab.
Age above 18 years, therapy for at least 2
months, same weekly dose of oral anticoagulant over the past 3 INR examinations
(maintenance therapy), and clinical follow up by AUBMC physicians.
Refusal of consent.